期刊文献+

瑞戈非尼有关物质的制备

Preparation of the Related Substances of Regorafenib
原文传递
导出
摘要 为控制瑞戈非尼的质量,制备8个工艺杂质:4-[3-氟-4-[[(2-甲胺甲酰基)吡啶-4-基]氨基]苯氧基]-N-甲基吡啶-2-甲酰胺(7)、4-氨基-3-(4-氨基-3-氟苯氧基)苯酚(8)、4-[4-氨基-3-(4-氨基-3-氟苯氧基)苯氧基]-N-甲基吡啶-2-甲酰胺(9)、N,N’-双[[3-氟-4-(2-甲胺基羰基吡啶-4-基)氧基]苯基]脲(10)、4-[4-[[4-氯-3-(三氟甲基)-苯基]氨基甲酰胺基]-3-[4-[[4-氯-3-(三氟甲基)苯基]氨基甲酰胺基]-3-氟苯氧基]苯氧基]-N-甲基吡啶-2-甲酰胺(11)、[4-氯-3-(三氟甲基)苯胺基]甲酸乙酯(12)、[4-氯-3-(三氟甲基)苯胺基]甲酸(13)及4-[[4-[4-氯-3-(三氟甲基)苯基]氨基甲酰胺基]苯氧基]-N-甲基吡啶-2-甲酰胺(15)。其中有关物质8、10、12及13未见文献报道。以上有关物质的结构均经~1H NMR和MS确证,可作为瑞戈非尼质量研究的对照物。 To perform the quality control of regorafenib,eight related substances were prepared. These substances were 4-[3-fluoro-4-[[2-(methylcarbamoyl)pyridin-4-yl]amino]phenoxy]-N-methylpyridin-2-carboxamide(7), 4-amino-3-(4-amino-3-fluorophenoxy)phenol(8), 4-[4-amino-3-(4-amino-3-fluorophenoxy)phenoxy]-Nmethylpyridin-2-carboxamide(9), N,N’-bis[[3-fluoro-4-[[2-(methylamino)carbonyl]-4-pyridinyl]oxy]phenyl]-urea(10), 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]aminoformamido]-3-[4-[[4-chloro-3-(trifluoromethyl)-phenyl]-aminoformamido]-3-fluorophenoxy]phenoxy]-N-methylpyridin-2-carboxamide(11), ethyl [4-chloro-3-(trifluoromethyl)-phenyl]carbamate(12),[4-chloro-3-(trifluoromethyl)phenyl]carbamic acid(13), and4-[[4-[4-chloro-3-(trifluoromethyl)phenyl]aminoformamido]phenoxy]-N-methylpyridin-2-carboxamide(15). The related substances 8, 10, 12 and 13 have not been reported in literature. The structures of the above related substances were confirmed by ~1H NMR and MS, which could be used for conference of regorafenib quality control.
作者 徐茂红 汤君 张强 王奎 刘为中 XU Maohong;TANG Jun;ZHANG Qiang;WANG Kui;LIU Weizhong(West Anhui Health Vocational College, Lu'an 237000;Hefei Industrial Pharmaceutical Institute Co., Ltd., Hefei 230601)
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2019年第6期632-637,共6页 Chinese Journal of Pharmaceuticals
关键词 瑞戈非尼 激酶抑制剂 有关物质 制备 regorafenib kinase inhibitor related substances synthesis
  • 相关文献

参考文献6

二级参考文献37

  • 1刘亚方,李洪玉,李金岭,姜申德.瑞格拉非尼(Regorafenib)的合成[J].精细化工中间体,2012,42(6):31-34. 被引量:7
  • 2赵乘有,陈林捷,许煦,罗晓燕,冀亚飞.对甲苯磺酸索拉非尼的合成[J].中国医药工业杂志,2007,38(9):614-616. 被引量:15
  • 3Bayer Pharmaceuticals Corporation. Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions :WO ,2005009961 [ P ]. 2005 -02 -03.
  • 4Bayer Healthcare AG. 4- [ 4 - ( { [ 4-Chloro-3 - ( trifluoromethyl ) phenyl] carbamoyl I amino ) -3-fluorophenoxy ] -N-methylpyri- dine-2-carboxamide monohydrate: WO, 2008043446 [ P ]. 2008 - 04 - 17.
  • 5WILHELM S M, DUMAS J, ADNANE L, et al. Regorafenib (BAY 73-4506 ):a new oral multikinase inhibitor of angio- genic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity [J ]. Int J Cancer, 2011, 129:245 - 255.
  • 6GROTHEY A, van CUTSEM E, SOBRERO A, et al. Rego- rafenib monotherapy for previously treated metastatic colorec- tal cancer (CORRECT) : an international, multicentre, random- ised,placebo-controlled, phase 3 trial [ EB/OL ]. [ 2012 - 11 - 22 ]. http ://dx. doi. org/10.1016/S0140-6736 (12) 61900-X.
  • 7Dirk S,Beate S. Regorafenib for cancer[J].Expert Opinion on Investigational Drugs,2012,(06):879-889.
  • 8Wilhelm S M,Dumas J,Adnane L. Regorafenib (BAY 73-4506):a new oral multikinase inhibitor of angiogenic,stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity[J].International Journal of Cancer,2011,(01):245-255.
  • 9Klaus M,Annette F,Simone S. A PhaseⅠ dose-escalation study of regorafenib (BAY 73-4506),an inhibitor of oncogenic,angiogenic,and stromal kinases,in patients with advanced solid tumors[J].Clinical Cancer Research,2012,(09):2658-2667.
  • 10Dumas J. Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf,VEGFR,PDGFR,p38 and fit-3 kinasemediated diseases[P].US,2005038080 A1,2005.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部